Aug 6, 2020IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021- May 27, 2020Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020
-
Mar 6, 2020Company planning to initiate a U.S. pivotal study of the C-Scan System in late 2020
-
Dec 30, 2019Advancing towards IDE submission to the FDA, targeting initiation of U.S. pivotal study in late 2020
